ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

Posted in Biotech by Medtech[y] Staff

June 15, 2020 • 2 min read

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPL...